Skip to main content
Premium Trial:

Request an Annual Quote

Merck KGaA, Millipore, PT Peptide Technologies

Premium
Germany's Merck KGaA to Use Cenix's RNAi Service to Screen for Drugs
 
Cenix BioScience this week said German drug maker Merck KGaA will use Cenix’s RNAi screening services in its target-discovery and -validation efforts in oncology, with an option to expand in several human disease programs.
 
Terms of the deal call for Cenix to perform high-throughput screens of cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
 
Financial terms of the deal were not disclosed.
 

 
Millipore to Market JPT Peptide's Enzyme Profiling Products
 
Millipore this week said that it will market and distribute JPT Peptide Technologies’ line of enzyme profiling products and services targeting enzymes such as kinases, phosphatases, and proteases.
 
JPT is a wholly owned subsidiary of Berlin-based Jerini. The non-exclusive deal is worldwide.
 
JPT's products “strongly complement our existing portfolio of cell signaling reagents and services,” Rick Ryan, vice president of the drug discovery business unit for the bioscience division of Millipore, said in a statement.
 
Financial terms of the deal were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.